Cipla, Stempeutics Research to launch Stempeucel for critical limb ischemia
Cipla announced that its partner Stempeutics Research has secured regulatory approval from the Drug Controller General of India (DCGI) for the launch of Stempeucel, a cell therapy for the treatment of critical limb ischemia (CLI), in India. Stempeucel has been indicated for the treatment of the condition caused by Buerger’s Disease and Atherosclerotic Peripheral Arterial […]